Betul Celik
Mayo Clinic
44 Papers
162 Citations
Betul Celik is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 8, co-authored 27 publications. Previous affiliations of Betul Celik include Health Science University.
Chat about Author
Papers
Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels
TL;DR: In this article, the first documentation of omalizumab use in ACOS was presented and the patients had a decreased IgE, fractional exhaled nitric oxide concentrations (FENO), eosinophil, neutrophils, macrophages, eosINophil cationic peptide (ECP) and sIL-4 levels.
47
Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
TL;DR: A case of a man with pruritic bullous pemphigoid (BP) and very high levels of total IgE (5000 kU/L) who was refractory to standard aggressive immunosuppressive regimens but responded rapidly to systemic anti-IgE (omalizumab).
44
Afirma GEC and thyroid lesions: An institutional experience
TL;DR: This study aimed to evaluate the Afirma Gene Expression Classifier (GEC) results for lesions in those categories where Bethesda category III (atypia of undetermined significance/follicular lesion of und determined significance) and category IV ( follicular neoplasm/suspicious for follicular neplasm) lesions are problematic.
41
Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution ☆ ☆☆
TL;DR: Nearly 29% of cases of RS/CSL diagnosed on image-guided CNB from January 1, 1994, to August 31, 2013, at a single institution were upstaged to invasive or in situ carcinoma or to atypical hyperplasia.
39
D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment.
TL;DR: In this article, the effect of omalizumab on bronchial and systemic vascular areas and evaluated SPA (group I) and CU (group II) patients before and after therapy period.
34